Literature DB >> 8159582

[Magnesium in the prophylaxis of primary headache and other periodic disorders in children].

S Castelli1, C Meossi, R Domenici, F Fontana, G Stefani.   

Abstract

Migraine has been recently defined a "central neuronal hyperexcitability state", maybe magnesium-dependent, and magnesium has been occasionally employed in the therapy of adult migraine. The Authors, on the basis of their personal experience (previous electromyographic studies), consider childhood migraine and periodic syndrome as a clinical equivalent of spasmophilia, in which an intracellular deficit of magnesium has been demonstrated, and have employed a magnesium salt in the prophylaxis of childhood migraine and migraine equivalents. 40 children with periodic syndrome (17 M and 23 F, aged 10.4 +/- 2.9 years) have been treated with magnesium pidolate, with doses ranging from 1.5 g/die to 4.5 g/die (corresponding to 122-366 mg Mg++):25 of them presented migraine as the main symptom, 12 recurrent abdominal pain, 3 fever of unknown origin, along with many other periodic symptoms. The first control visits have been done at 1 month, clinical follow-up lasted a mean period of 6.1 months. Therapy was stopped at 1 month visit if ineffective (of some other drug was added); otherwise, magnesium therapy was continued with the same dosage for another month, then gradually reduced. Clinical response was considered good if crises ceased completely or their frequency was reduced to less than 33%; partial if reduced to less than 67% of previous incidence; absent if only slightly or not at all reduced. Clinical response was good in 72.5% of cases at 1 month, in 77.5% later; partial in 12.5% and 10%; absent in 15% and 12.5% respectively. No side effects were observed. The compliance of children and their families was complete.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8159582

Source DB:  PubMed          Journal:  Pediatr Med Chir        ISSN: 0391-5387


  9 in total

1.  Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study.

Authors:  Maria Esposito; Marco Carotenuto
Journal:  Neurol Sci       Date:  2010-09-25       Impact factor: 3.307

Review 2.  The optimal management of headaches in children and adolescents.

Authors:  Joanne Kacperski; Marielle A Kabbouche; Hope L O'Brien; Jessica L Weberding
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

3.  Modulation of endothelin-1-induced contractions by magnesium/calcium in porcine ciliary arteries.

Authors:  E S Dettmann; T F Lüscher; J Flammer; I O Haefliger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1998-01       Impact factor: 3.117

4.  Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I.

Authors:  Marco Carotenuto; Maria Esposito
Journal:  Neurol Sci       Date:  2013-03-27       Impact factor: 3.307

Review 5.  Complementary and alternative treatments for childhood headaches.

Authors:  Stewart J Tepper
Journal:  Curr Pain Headache Rep       Date:  2008-10

Review 6.  The Evidence for the Role of Nutraceuticals in the Management of Pediatric Migraine: a Review.

Authors:  Serena L Orr
Journal:  Curr Pain Headache Rep       Date:  2018-04-04

7.  Magnesium as a preventive treatment for paediatric episodic tension-type headache: results at 1-year follow-up.

Authors:  L Grazzi; F Andrasik; S Usai; G Bussone
Journal:  Neurol Sci       Date:  2007-06-30       Impact factor: 3.307

Review 8.  Non-Pharmacological Approaches to Headaches: Non-Invasive Neuromodulation, Nutraceuticals, and Behavioral Approaches.

Authors:  Licia Grazzi; Claudia Toppo; Domenico D'Amico; Matilde Leonardi; Paolo Martelletti; Alberto Raggi; Erika Guastafierro
Journal:  Int J Environ Res Public Health       Date:  2021-02-05       Impact factor: 3.390

9.  Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial.

Authors:  Charly Gaul; Hans-Christoph Diener; Ulrich Danesch
Journal:  J Headache Pain       Date:  2015-04-03       Impact factor: 7.277

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.